Department of Urology, Yamada Red Cross Hospital, Ise, Mie,
Anticancer Res. 2011 Apr;31(4):1471-4.
Instillation of chemotherapy after transurethral resection (TUR) has been considered as an optimal treatment for non-muscle invasive bladder cancer (NMIBC). However, controversy remains regarding the role of chemotherapy instillation. We therefore evaluated the usefulness of continuous saline bladder irrigation (CSBI) after TUR.
Patients with intermediate risk NMIBC were treated by TUR followed by either CSBI (123 patients) or intravesical instillation of mitomycin C (115 patients). Recurrence-free rates were estimated using the Kaplan-Meier method.
No significant differences were observed in the recurrence-free rate, period to first recurrence, nor in frequency of recurrence between the CSBI and intravesical chemotherapy groups. Tumor progression rate and local toxicities were significantly higher in the intravesical chemotherapy group.
CSBI after TUR appears to be a prophylactic treatment choice for intermediate risk NMIBC patients, in terms of its equal prophylactic effect to intravesical chemotherapy with mitomycin C, and its safety and cost benefits.
经尿道切除术（TUR）后进行化疗灌注被认为是治疗非肌肉浸润性膀胱癌（NMIBC）的最佳方法。然而，关于化疗灌注的作用仍存在争议。因此，我们评估了 TUR 后持续生理盐水膀胱冲洗（CSBI）的作用。
采用 TUR 治疗中危 NMIBC 患者，然后进行 CSBI（123 例）或膀胱内注射丝裂霉素 C（115 例）。采用 Kaplan-Meier 法估计无复发生存率。
CSBI 组和膀胱内化疗组的无复发生存率、首次复发时间和复发频率均无显著差异。膀胱内化疗组的肿瘤进展率和局部毒性较高。
TUR 后行 CSBI 似乎是中危 NMIBC 患者的一种预防治疗选择，因为它与膀胱内注射丝裂霉素 C 的预防效果相当，且具有安全性和成本效益。
